查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995483

D-二聚體檢測市場：2026-2032年全球市場預測（按檢測類型、技術、檢體類型、應用和最終用戶分類）

D-dimer Testing Market by Test Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，D-二聚體檢測市場價值將達到 16.5 億美元，到 2026 年將成長至 17.4 億美元，到 2032 年將達到 25.4 億美元，複合年成長率為 6.33%。

主要市場統計數據
基準年 2025 16.5億美元
預計年份：2026年 17.4億美元
預測年份 2032 25.4億美元
複合年成長率 (%) 6.33%

這篇重點介紹說明了臨床需求、技術進步和操作要求如何改變醫療保健環境中的 D-二聚體診斷過程。

D-二聚體檢測已成為現代診斷流程中不可或缺的一部分，為急診、住院病房和門診的臨床決策提供支援。 D-二聚體檢測最初是作為檢測纖維蛋白分解產物而開發的，隨著檢測技術、快速照護現場（POC​​）平台和綜合臨床演算法的進步，其應用也日益廣泛。本文概述了D-二聚體診斷對醫療專業人員和相關人員的臨床應用效用、營運影響和策略意義。

臨床演算法、技術創新和不斷變化的報銷趨勢如何重新定義 D-二聚體檢測在診斷和患者管理中的應用。

由於臨床、技術和政策等多面向因素的共同作用，D-二聚體檢測的現狀正經歷著變革性的轉變。臨床上，更新的診斷流程強調風險分層和選擇性影像檢查，更依賴高靈敏度檢測方法，並要求結果解讀的一致性。這促使各醫療機構制定標準化的檢測通訊協定，並在相關的患者群體中驗證檢驗效能。同時，檢測化學和自動化技術的進步提高了分析準確性，從而降低了檢測閾值，並提高了血栓性疾病的陰性預測值。

2025 年美國關稅政策變更對營運和採購的影響，以及這些變化如何影響診斷供應鏈的韌性和籌資策略。

2025年美國關稅調整和貿易政策轉變的累積影響正在重塑D-二聚體檢測相關診斷設備和耗材的籌資策略。試劑、儀器組件和完整診斷平台的進口成本不斷上漲，迫使檢查室和醫療系統重新思考其採購方式、物流規劃以及供應商多元化的努力。對於依賴國際供應鏈取得試劑組和專用檢測組件的機構而言，這些商業性壓力尤其嚴峻，導致它們更加重視庫存管理和合約重新談判。

詳細的細分分析表明，測試類型、檢測技術、檢體基質、臨床環境和應用如何獨特地影響採用趨勢和產品策略。

細分市場層面的趨勢揭示了每種檢測類型、技術、檢體類型、最終用戶和應用的不同價值來源，這些價值來源共同影響臨床應用和商業性定位。就檢測類型而言，檢查室檢測和即時檢測 (POC) 解決方案之間已形成清晰的二分法，從而形成了不同的應用場景。集中式檢查室平台優先考慮處理能力、分析準確性和與實驗室資訊系統的整合，而 POC 解決方案則強調快速出結果、便攜性以及直接向臨床醫生呈現結果。就技術而言，化學冷光免疫檢測法憑藉其自動化工作流程和高靈敏度，常用於高通量檢查室。酵素免疫分析法(ELISA) 為專業檢測和實驗室研究提供了柔軟性。螢光免疫分析支援緊湊、高靈敏度的系統，適用於患者現場使用和中心檢查室部署。在優先考慮簡便性和成本效益的情況下，乳膠凝集測試仍然非常重要。

影響美洲、歐洲、中東和非洲以及亞太地區採用、監管和籌資策略的區域趨勢和市場促進因素

區域趨勢對關鍵地區D-二聚體檢測解決方案的需求模式、監管預期和競爭格局的形成至關重要。美洲地區的特點是臨床應用日益普及，急診醫學領域越來越重視照護現場檢測，以及支付方對成本效益和臨床療效的要求日益提高。該地區的實驗室和醫院通常尋求兼具檢測性能和營運效率的整合解決方案，而製造商則優先考慮符合國家標準，以促進市場准入。

競爭格局分析，重點在於成熟公司、專業開發公司和即時照護創新者如何透過技術、夥伴關係和證據產生來實現差異化。

D-二聚體檢測市場由成熟的診斷公司、專業檢測開發商和新興的即時檢測（POC​​T）參與企業之間的競爭所構成。成熟的製造商憑藉其在臨床檢查室的良好口碑、豐富的試劑產品組合以及支援高通量中心檢測的全球服務網路，保持強大的市場競爭力。這些成熟企業充分利用其與檢查室自動化和資訊系統整合的能力作為競爭優勢，同時不斷投資改進檢測性能，以鞏固其在醫院系統和參考實驗室的地位。

診斷試劑製造商和醫療保健提供者的具體策略重點，以最大限度地提高 D-二聚體檢測的臨床應用、供應彈性和商業性影響。

產業領導企業應優先考慮一系列切實可行的策略，使商業性執行與臨床影響和營運實際情況相符。首先，他們應投資於有針對性的臨床證據項目，量化特定D-二聚體檢測對患者診療路徑、影像檢查利用率和住院時長等指標的影響。這些研究應結合具體情境，並與最終使用者合作設計，以確保其相關性和可靠性。其次，他們應開發靈活的商業模式，降低推廣應用的資金門檻，例如試劑租賃協議、基於結果的定價或基於訂閱的數據分析和支援服務。這些模式在提高可近性的同時，也能讓供應商的獎勵與檢查室的效能和運轉率一致。

研究採用嚴謹的混合方法，結合對現場相關人員的訪談、對臨床文獻的回顧以及交叉檢驗的分析方法，以產生實用的診斷見解。

本研究整合了一級資訊來源和二級資訊來源資料，以確保研究的嚴謹性和相關性。一級資訊來源包括對實驗室主任、臨床病理學家、急診醫生、採購負責人和產品經理等利益相關者的訪談，並輔以現場相關人員，以了解工作流程的限制和推廣應用的障礙。透過這些直接參與，我們獲得了關於實際檢測效能、預期回應時間和採購決策標準的定性見解。第二手資料包括同行評審的臨床文獻、監管文件、醫療設備使用手冊以及公開的臨床指南，這些資料提供了有關檢測的效用和推薦診斷流程的資訊。

一項權威的綜合分析重點闡述了臨床價值、營運韌性和互通性解決方案如何決定 D-二聚體診斷生態系統的長期成功。

這項綜合分析強調，D-二聚體檢測在臨床需求、技術創新和營運決策這三大要素的交匯點上佔據著策略性地位。高靈敏度檢測和快速照護現場方案並非相互排斥，而是相輔相成，從而能夠實現循序漸進的診斷方法，使分析能力與臨床需求相符。隨著支付方和醫療服務提供者將重點放在以價值為導向的醫療和高效的資源利用上，證明D-二聚體檢測如何減少不必要的影像檢查並簡化患者就診流程的證據，將在塑造其應用模式方面發揮關鍵作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 D-二聚體檢測市場（依檢測類型分類）

  • 檢查室基地
  • 照護端

第9章：D-二聚體檢測市場：依技術分類

  • 化學冷光免疫檢測
  • 酵素免疫分析法
  • 螢光免疫分析
  • 乳膠凝集測試

第10章檢體類型分類的D-二聚體檢測市場

  • 電漿
  • 血清
  • 全血

第11章：D-二聚體檢測市場：依應用領域分類

  • 瀰漫性血管內凝血
  • 中風
  • 靜脈血栓栓塞症

第12章：D-二聚體檢測市場：依最終用戶分類

  • 門診手術中心
  • 診斷檢查室
  • 醫院

第13章：D-二聚體檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：D-二聚體檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：D-二聚體檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國D-二聚體檢測市場

第17章：中國D-二聚體檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • DiaSorin SpA
  • Instrumentation Laboratory Company
  • Ortho Clinical Diagnostics Inc.
  • Roche Diagnostics GmbH
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-FB6C9E792A6C

The D-dimer Testing Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.74 billion in 2026, with a CAGR of 6.33%, reaching USD 2.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.74 billion
Forecast Year [2032] USD 2.54 billion
CAGR (%) 6.33%

A focused introduction explaining how clinical necessity, technological advances, and operational demands are reshaping D-dimer diagnostic pathways in care settings

D-dimer testing has become an essential element of modern diagnostic pathways, informing clinical decision-making across emergency departments, inpatient wards, and ambulatory settings. Initially developed as a laboratory assay to detect fibrin degradation products, D-dimer testing has evolved in parallel with advances in assay technology, rapid point-of-care platforms, and integrated clinical algorithms. This introduction outlines the clinical utility, operational implications, and strategic relevance of D-dimer diagnostics for healthcare providers and industry stakeholders.

Clinically, elevated D-dimer levels remain a sensitive indicator for thrombotic events such as venous thromboembolism and are used to triage patients for further imaging or anticoagulation therapy. Over time, the role of the test has broadened to include screening for disseminated intravascular coagulation and adjunctive evaluation of stroke patients. From an operational perspective, the availability of both laboratory-based assays and rapid point-of-care options has created new choices for care pathways where speed and decentralization of testing influence throughput and clinical outcomes. As a result, hospital laboratories, diagnostic centers, and ambulatory surgical units must balance analytical performance with turnaround time and workflow integration.

Strategically, industry participants and clinical leaders are navigating an environment shaped by changing reimbursement paradigms, evolving clinical guidelines, and technology-driven differentiation. Innovations in assay chemistries and automation are redefining performance benchmarks, while emerging point-of-care solutions are challenging traditional centralized testing models. This section frames the subsequent deeper analysis by highlighting the clinical drivers, technological enablers, and institutional considerations that make D-dimer testing a focal point for diagnostic strategy and investment.

How clinical algorithms, technological innovation, and evolving reimbursement dynamics are collectively redefining diagnostics and patient management with D-dimer testing

The landscape of D-dimer testing is experiencing transformative shifts driven by converging clinical, technological, and policy forces. Clinically, updated diagnostic algorithms emphasize risk stratification and selective imaging, increasing reliance on high-sensitivity assays and consistent result interpretation. This creates pressure to standardize testing protocols across institutions and to validate assay performance within relevant patient cohorts. Simultaneously, improvements in assay chemistries and automation have elevated analytical precision, enabling lower detection thresholds and improving negative predictive value for thrombotic conditions.

On the technology front, the proliferation of rapid point-of-care platforms is enabling diagnostic decentralization and facilitating decision-making at the bedside or in ambulatory settings. These devices reduce time-to-result and can influence patient flow, particularly in emergency departments where timely disposition is critical. Moreover, advances in chemiluminescence immunoassays, fluorescence immunoassays, and enzyme-linked immunosorbent approaches are generating differentiated value propositions for central laboratories, whereas latex agglutination methods continue to offer cost-effective alternatives in specific contexts.

Policy and reimbursement landscapes are also shifting, with payers and regulators increasingly focusing on evidence of clinical utility and cost-effectiveness. These changes favor integrated diagnostic solutions that demonstrably reduce unnecessary imaging and downstream costs. As a result, manufacturers and clinical labs are investing in real-world evidence generation and collaborative studies to validate diagnostic pathways. Together, these clinical, technological, and policy shifts are redefining competitive dynamics and creating opportunities for solutions that blend analytical robustness with operational agility.

Assessing the operational and procurement consequences of US tariff shifts in 2025 and how they are driving supply chain resilience and sourcing strategies for diagnostics

The cumulative effect of tariff adjustments and trade policy shifts in the United States during 2025 is reshaping procurement strategies for diagnostic equipment and consumables connected to D-dimer testing. Heightened import costs for reagents, instrumentation components, and finished diagnostic platforms have prompted laboratories and health systems to reassess sourcing approaches, logistics planning, and supplier diversification efforts. These commercial pressures are particularly acute for facilities that rely on international supply chains for reagent kits and specialized assay components, leading to an increased focus on inventory management and contract renegotiation.

In response to tariff-related cost burdens, many stakeholders are pursuing operational adaptations such as consolidating procurement volumes with preferred suppliers, exploring domestic manufacturing partnerships, and prioritizing assays that minimize consumable complexity. Clinical laboratories are evaluating the total cost of ownership more rigorously, weighing instrument amortization, reagent shelf-life, and service support against unit test costs. These dynamics have also encouraged vendors to introduce bundled solutions and flexible commercial models, including reagent rental agreements and performance-based contracts that mitigate up-front capital exposure.

The net effect on clinical delivery is a heightened emphasis on resilience and supply-chain transparency. Health systems are instituting dual-sourcing strategies and expanding in-house validation capabilities to reduce service disruption risk. At the same time, vendors are accelerating localization efforts and exploring alternative materials or assay formats that are less vulnerable to tariff volatility. Collectively, these responses are guiding a pragmatic rebalancing of cost, quality, and operational continuity across the diagnostic ecosystem.

Deep segmentation insights showing how test type, assay technologies, sample matrices, clinical settings, and applications uniquely shape adoption and product strategy

Segment-level dynamics reveal differentiated value drivers across test type, technology, sample type, end user, and application, each of which shapes clinical adoption and commercial positioning. In terms of test type, the dichotomy between laboratory-based assays and point-of-care solutions creates distinct use case pathways: centralized laboratory platforms prioritize throughput, analytic precision, and integration with laboratory information systems, while point-of-care options emphasize rapid turnaround, portability, and direct clinician-facing results. Concerning technology, chemiluminescence immunoassays frequently serve high-volume laboratories with automated workflows and enhanced sensitivity; enzyme-linked immunosorbent assays offer flexibility for specialized testing and research contexts; fluorescence immunoassays support compact, sensitive systems suitable for both near-patient and central lab deployment; and latex agglutination methods remain relevant where simplicity and cost containment are prioritized.

Sample type considerations also drive procurement and workflow choices. Plasma samples are commonly used in centralized lab workflows for their compatibility with automated analyzers and standardized processing; serum is selected in settings where coagulation control and sample stability matter; and whole blood is pivotal for point-of-care environments where immediate testing without centrifugation streamlines clinical decision-making. End user segmentation sheds light on setting-specific requirements: ambulatory surgical centers demand rapid, reliable assays that support same-day procedures and minimize cancellations; diagnostic laboratories require high-throughput, validated platforms that integrate into existing automation tracks; and hospitals need a mixture of centralized and near-patient capabilities to support emergency, inpatient, and perioperative workflows. Finally, application-driven insights emphasize clinical priorities: tests used for disseminated intravascular coagulation require robust sensitivity and dynamic range to capture coagulation abnormalities; stroke applications necessitate fast turnaround and compatibility with acute care algorithms; and venous thromboembolism evaluation benefits from high negative predictive value and standardized interpretive criteria. Taken together, these segmentation perspectives inform product design, go-to-market strategies, and clinical validation priorities for stakeholders seeking to align offerings with distinct care settings and diagnostic objectives.

Regional dynamics and market drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, regulation, and procurement strategies

Regional dynamics are pivotal in shaping demand patterns, regulatory expectations, and the competitive landscape for D-dimer testing solutions across major geographies. The Americas region is characterized by advanced clinical adoption, growing emphasis on point-of-care deployment in emergency medicine, and payer environments that increasingly require evidence of cost-effectiveness and clinical impact. Laboratories and hospitals in this region often pursue integrated solutions that link assay performance with operational efficiency, and manufacturers prioritize regulatory alignment with national standards to facilitate market access.

In Europe, Middle East & Africa, fragmentation in healthcare systems and regulatory harmonization efforts create a complex market environment. In some European markets, centralized procurement and strong laboratory infrastructures favor high-throughput laboratory assays, while other markets within the region place greater emphasis on decentralized testing due to access constraints. Regulatory pathways vary widely across the region, which affects timelines for product introduction and necessitates tailored clinical validation strategies. In many parts of the region, price sensitivity and logistics considerations influence the balance between point-of-care convenience and centralized analytical rigor.

The Asia-Pacific region is notable for rapid adoption curves, significant investments in healthcare infrastructure, and a heterogeneous mix of urban tertiary centers and rural clinics. Demand for both high-throughput laboratory platforms and affordable rapid tests is strong, driven by the need to improve acute care triage and reduce diagnostic delays. Local manufacturing and regulatory initiatives in several countries are fostering domestic production capabilities and shortening time-to-market for region-specific solutions. Across all regions, collaboration between manufacturers, clinicians, and procurement bodies is instrumental in aligning product capabilities with clinical workflows and reimbursement realities, thereby accelerating appropriate adoption and sustainable utilization.

Competitive landscape analysis emphasizing how incumbents, specialized developers, and point-of-care innovators are differentiating through technology, partnerships, and evidence generation

Competitive dynamics among established diagnostic companies, specialized assay developers, and emerging point-of-care entrants are shaping the D-dimer testing marketplace. Legacy manufacturers maintain strength through installed bases in clinical laboratories, broad reagent portfolios, and global service networks that support high-volume central testing. These incumbents leverage integration capabilities with laboratory automation and information systems as a competitive moat, while investing in incremental assay performance improvements to preserve relevance in hospital systems and reference laboratories.

At the same time, specialized assay developers and niche vendors are advancing differentiated chemistries and compact platforms that address unmet clinical needs, particularly in rapid triage and decentralized care. These players often emphasize speed-to-result, ease-of-use, and minimal sample processing as core selling points. Startups and point-of-care entrants are challenging traditional models by focusing on clinician-centric design, simplified user interfaces, and connectivity features that feed directly into electronic medical records and clinical decision support systems. Strategic partnerships, co-development agreements, and channel diversification are common tactics deployed across the competitive landscape to accelerate market penetration and to overcome regulatory and reimbursement hurdles.

Across all company types, evidence generation through clinical studies, real-world validations, and health economic assessments is a central differentiator. Firms that can demonstrate consistent analytical performance, workflow benefits, and measurable reductions in downstream imaging or hospitalization are better positioned to secure formulary placements and institutional buy-in. As the ecosystem evolves, collaboration between manufacturers and healthcare institutions on piloting new deployment models will continue to influence which companies capture long-term value.

Actionable strategic priorities for diagnostic manufacturers and healthcare providers to maximize clinical adoption, supply resilience, and commercial impact for D-dimer testing

Industry leaders should prioritize a set of actionable strategies that align commercial execution with clinical impact and operational realities. First, invest in targeted clinical evidence initiatives that quantify how specific D-dimer assays influence patient pathways, imaging utilization, and length-of-stay metrics. These studies should be context-specific and designed in collaboration with end users to ensure relevance and credibility. Second, develop flexible commercial models that reduce capital barriers for adoption, such as reagent rental agreements, outcome-linked pricing, or subscription-based access to data analytics and support services. Such models increase accessibility while aligning supplier incentives with laboratory performance and uptime.

Third, strengthen supply chain resilience by diversifying manufacturing footprints and creating contingency sourcing plans for critical reagents and components. Transparent communication with institutional buyers about lead times and risk mitigation measures will build trust and reduce procurement friction. Fourth, prioritize seamless integration with clinical workflows through interoperability with laboratory information systems and electronic health records, as well as by providing training and support that accelerates adoption. Fifth, tailor go-to-market approaches by end-user segment: hospitals will value integrated laboratory solutions and service support; diagnostic laboratories will prioritize throughput and automation compatibility; ambulatory surgical centers will seek rapid, reliable assays that minimize procedural delays.

Finally, pursue regulatory and reimbursement strategies that emphasize clinical utility and health economic benefit. Engaging early with payers and health technology assessment bodies to present robust value propositions can shorten commercialization timelines and improve uptake. By executing on these priorities, industry leaders can translate technological advantages into sustainable market positions and demonstrable improvements in patient care.

A rigorous mixed-methods research approach combining frontline stakeholder interviews, clinical literature review, and cross-validated analytical techniques to produce actionable diagnostics insights

This research synthesizes evidence from a combination of primary and secondary sources to ensure rigor and relevance. Primary inputs include stakeholder interviews with laboratory directors, clinical pathologists, emergency medicine physicians, procurement professionals, and product managers, supplemented by site visit observations to understand workflow constraints and adoption barriers. These direct engagements provide qualitative insights into real-world assay performance, turnaround time expectations, and procurement decision criteria. Secondary sources encompass peer-reviewed clinical literature, regulatory filings, device instructions for use, and publicly available clinical guidelines that inform assay utility and recommended diagnostic algorithms.

Data synthesis involved cross-validation between qualitative insights and documented evidence to identify consensus themes and to flag areas of divergence requiring further investigation. Analytical methods included comparative technology assessment, end-user mapping to clinical workflows, and scenario-based evaluation of supply-chain impacts under varying tariff conditions. Quality control measures comprised methodological triangulation, repeated stakeholder validation sessions, and internal peer review to ensure findings are robust and defensible. Limitations of the approach include variable availability of proprietary commercial data and the dynamic nature of regulatory and reimbursement landscapes, which can evolve after primary data collection.

To mitigate these limitations, the research incorporates sensitivity checks and documents assumptions underlying interpretive conclusions. Where possible, recommendations are framed to be resilient to short-term market fluctuations and to emphasize operational levers that stakeholders can control. This methodology enables practical, evidence-based insights that healthcare leaders and commercial teams can apply to decision-making around D-dimer testing strategies.

A conclusive synthesis highlighting how clinical value, operational resilience, and interoperable solutions determine long-term success in the D-dimer diagnostics ecosystem

The cumulative analysis underscores that D-dimer testing occupies a strategic intersection of clinical necessity, technological innovation, and operational decision-making. High-sensitivity assays and rapid point-of-care solutions are not mutually exclusive but complementary, enabling a tiered diagnostic approach that aligns analytical performance with care setting requirements. As payers and providers emphasize value-based care and efficient resource utilization, evidence demonstrating how D-dimer testing reduces unnecessary imaging and streamlines patient flow will be decisive in shaping adoption patterns.

Operationally, supply-chain resilience and procurement flexibility are critical enablers of uninterrupted testing capacity. Laboratories and health systems that proactively manage sourcing channels and that engage with vendors on performance-based contracting will be better positioned to maintain continuity in the face of tariff or logistic disruptions. From a competitive standpoint, companies that marry robust analytical performance with clinician-focused usability and interoperable data architectures will secure stronger institutional partnerships and adoption momentum.

In conclusion, stakeholders should view D-dimer testing not merely as a single assay but as an element within broader diagnostic pathways that require coordinated clinical, operational, and commercial strategies. The organizations that succeed will be those that can demonstrate real-world clinical value, manage supply and cost pressures pragmatically, and deliver solutions that integrate seamlessly into heterogeneous care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. D-dimer Testing Market, by Test Type

  • 8.1. Laboratory Based
  • 8.2. Point Of Care

9. D-dimer Testing Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme Linked Immunosorbent Assay
  • 9.3. Fluorescence Immunoassay
  • 9.4. Latex Agglutination

10. D-dimer Testing Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. D-dimer Testing Market, by Application

  • 11.1. Disseminated Intravascular Coagulation
  • 11.2. Stroke
  • 11.3. Venous Thromboembolism

12. D-dimer Testing Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals

13. D-dimer Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. D-dimer Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. D-dimer Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States D-dimer Testing Market

17. China D-dimer Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Beckman Coulter, Inc.
  • 18.7. bioMerieux SA
  • 18.8. DiaSorin S.p.A
  • 18.9. Instrumentation Laboratory Company
  • 18.10. Ortho Clinical Diagnostics Inc.
  • 18.11. Roche Diagnostics GmbH
  • 18.12. Siemens Healthineers AG
  • 18.13. Sysmex Corporation
  • 18.14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL D-DIMER TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL D-DIMER TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL D-DIMER TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL D-DIMER TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL D-DIMER TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL D-DIMER TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL D-DIMER TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL D-DIMER TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL D-DIMER TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL D-DIMER TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL D-DIMER TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL D-DIMER TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL D-DIMER TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL D-DIMER TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL D-DIMER TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL D-DIMER TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL D-DIMER TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL D-DIMER TESTING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL D-DIMER TESTING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL D-DIMER TESTING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL D-DIMER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL D-DIMER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL D-DIMER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL D-DIMER TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL D-DIMER TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL D-DIMER TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL D-DIMER TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL D-DIMER TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL D-DIMER TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL D-DIMER TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL D-DIMER TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL D-DIMER TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL D-DIMER TESTING MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL D-DIMER TESTING MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL D-DIMER TESTING MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL D-DIMER TESTING MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL D-DIMER TESTING MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL D-DIMER TESTING MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL D-DIMER TESTING MARKET SIZE, BY VENOUS THROMBOEMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL D-DIMER TESTING MARKET SIZE, BY VENOUS THROMBOEMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL D-DIMER TESTING MARKET SIZE, BY VENOUS THROMBOEMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL D-DIMER TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL D-DIMER TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL D-DIMER TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL D-DIMER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL D-DIMER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL D-DIMER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL D-DIMER TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL D-DIMER TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL D-DIMER TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL D-DIMER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS D-DIMER TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL D-DIMER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. GCC D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. GCC D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. NATO D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)